CN110446505A - 用于治疗皮肤病的联合疗法 - Google Patents

用于治疗皮肤病的联合疗法 Download PDF

Info

Publication number
CN110446505A
CN110446505A CN201880019777.9A CN201880019777A CN110446505A CN 110446505 A CN110446505 A CN 110446505A CN 201880019777 A CN201880019777 A CN 201880019777A CN 110446505 A CN110446505 A CN 110446505A
Authority
CN
China
Prior art keywords
substituted
composition
unsubstituted diindolylmethane
diindolylmethane
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880019777.9A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·C·斯凯夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skintech Life Science Ltd
Original Assignee
Skintech Life Science Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skintech Life Science Ltd filed Critical Skintech Life Science Ltd
Priority to CN202310057791.0A priority Critical patent/CN116036290A/zh
Publication of CN110446505A publication Critical patent/CN110446505A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880019777.9A 2017-01-20 2018-01-19 用于治疗皮肤病的联合疗法 Pending CN110446505A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310057791.0A CN116036290A (zh) 2017-01-20 2018-01-19 用于治疗皮肤病的联合疗法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448808P 2017-01-20 2017-01-20
US62/448,808 2017-01-20
PCT/IB2018/000109 WO2018134683A1 (en) 2017-01-20 2018-01-19 Combination therapy for treatment of skin diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310057791.0A Division CN116036290A (zh) 2017-01-20 2018-01-19 用于治疗皮肤病的联合疗法

Publications (1)

Publication Number Publication Date
CN110446505A true CN110446505A (zh) 2019-11-12

Family

ID=61731720

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880019777.9A Pending CN110446505A (zh) 2017-01-20 2018-01-19 用于治疗皮肤病的联合疗法
CN202310057791.0A Pending CN116036290A (zh) 2017-01-20 2018-01-19 用于治疗皮肤病的联合疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310057791.0A Pending CN116036290A (zh) 2017-01-20 2018-01-19 用于治疗皮肤病的联合疗法

Country Status (8)

Country Link
US (2) US11241467B2 (enExample)
EP (1) EP3570889A1 (enExample)
JP (2) JP7123058B2 (enExample)
CN (2) CN110446505A (enExample)
AU (1) AU2018209393B2 (enExample)
BR (1) BR112019014942A2 (enExample)
CA (1) CA3050208A1 (enExample)
WO (1) WO2018134683A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2741577C2 (ru) * 2016-09-15 2021-01-27 Скинтек Лайф Сайенс Лимитед Сублингвальное или буккальное введение dim для лечения заболеваний кожи
US11241467B2 (en) 2017-01-20 2022-02-08 Skintech Life Science Limited Composition for treating acne
US20250134803A1 (en) * 2023-11-01 2025-05-01 Skintech Life Science Limited Topical dim compositions and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665367A (en) * 1996-09-27 1997-09-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions containing naringenin and/or quercetin and a retinoid
WO2012130698A1 (en) * 2011-03-25 2012-10-04 Iiaa Limited Composition comprising a diindolylmethane and a retinoid to treat a skin condition
CN102858337A (zh) * 2010-04-26 2013-01-02 韦莱斯法尔马股份公司 用于治疗人类增生性和炎症性疾病的基于二吲哚基甲烷的药物
WO2014177123A1 (de) * 2013-04-30 2014-11-06 Melnik Bodo C Akne-medikament und verfahren zu seiner herstellung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599913B1 (en) * 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions
US6767563B2 (en) * 2001-10-30 2004-07-27 Michael D. Farley Immune functions
US20030166583A1 (en) * 2002-02-22 2003-09-04 Oliver Yoa-Pu Hu Dermal cytochrome P450 1A inhibitors and enhancers
BRPI0717753B1 (pt) * 2006-10-27 2022-04-12 Bioresponse, Llc Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição
FR2908604B1 (fr) * 2006-11-16 2013-06-28 Physcience Complement alimentaire pour la prevention ou la lutte contre la chute des cheveux, l'acne, l'hirsutisme et la secretion sudorale apocrine excessive.
SG193928A1 (en) * 2011-04-12 2013-11-29 Nestec Sa Nutritional compositions including branched chain fatty acids for improving gut barrier function
US20160051536A1 (en) * 2013-04-08 2016-02-25 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
GB2528482A (en) * 2014-07-23 2016-01-27 Skintech Life Science Ltd Pharmaceutical agent
RU2741577C2 (ru) * 2016-09-15 2021-01-27 Скинтек Лайф Сайенс Лимитед Сублингвальное или буккальное введение dim для лечения заболеваний кожи
US11241467B2 (en) 2017-01-20 2022-02-08 Skintech Life Science Limited Composition for treating acne

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665367A (en) * 1996-09-27 1997-09-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions containing naringenin and/or quercetin and a retinoid
CN102858337A (zh) * 2010-04-26 2013-01-02 韦莱斯法尔马股份公司 用于治疗人类增生性和炎症性疾病的基于二吲哚基甲烷的药物
WO2012130698A1 (en) * 2011-03-25 2012-10-04 Iiaa Limited Composition comprising a diindolylmethane and a retinoid to treat a skin condition
CN103501772A (zh) * 2011-03-25 2014-01-08 Iiaa有限公司 用于治疗皮肤病症的包含二吲哚基甲烷和类视黄醇的组合物
WO2014177123A1 (de) * 2013-04-30 2014-11-06 Melnik Bodo C Akne-medikament und verfahren zu seiner herstellung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
和凡等: ""槲皮素、山奈酚、芦丁对大鼠肝微粒体细胞色素P450酶的诱导作用"", 《中国医院药学杂志》 *

Also Published As

Publication number Publication date
AU2018209393A1 (en) 2019-08-08
JP2022169626A (ja) 2022-11-09
WO2018134683A1 (en) 2018-07-26
CA3050208A1 (en) 2018-07-26
JP7123058B2 (ja) 2022-08-22
RU2019124938A3 (enExample) 2021-05-27
EP3570889A1 (en) 2019-11-27
JP2020506169A (ja) 2020-02-27
BR112019014942A2 (pt) 2020-04-14
CN116036290A (zh) 2023-05-02
JP7481402B2 (ja) 2024-05-10
US20220193167A1 (en) 2022-06-23
US11241467B2 (en) 2022-02-08
AU2018209393B2 (en) 2024-02-15
US20200138884A1 (en) 2020-05-07
RU2019124938A (ru) 2021-02-20

Similar Documents

Publication Publication Date Title
JP7481402B2 (ja) 皮膚疾患の処置のための併用療法
Korting et al. Current topical and systemic approaches to treatment of rosacea
Cajaraville Ibuprofen arginate for rapid-onset pain relief in daily practice: A review of its use in different pain conditions
US10058519B2 (en) Treatment of pain with topical diclofenac
CN106604725A (zh) 治疗肥胖症，防止体重增加，促进体重减轻，促进减肥，或治疗或预防糖尿病的发展的方法和组合物
US20240390326A1 (en) Sublingual or buccal administration of dim for treatment of skin diseases
KR20220123224A (ko) 로페콕시브의 신규 투여 형태 및 관련 방법
PT2114392E (pt) Uso de adapaleno e peróxido de benzoíla para o tratamento a longo prazo da acne vulgaris
US8546450B1 (en) Treatment of pain with topical diclofenac compounds
RU2775974C2 (ru) Комбинированная терапия для лечения кожных заболеваний
HK40011827A (en) Combination therapy for treatment of skin diseases
JP5969787B2 (ja) 生体内のメイラード反応抑制剤またはＡＧＥｓ生成抑制剤
JP6170653B2 (ja) トラネキサム酸を含有する生体内のメイラード反応抑制剤組成物
JP2010077102A (ja) 高齢者向け機能食品および医薬組成物
CN110996937A (zh) 包含dgla的药物组合物及其用途
JP2012188417A (ja) ＡＧＥｓ生成抑制剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011827

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20191112

RJ01 Rejection of invention patent application after publication